Dr. Brian D. Moseley

Neurology and Rehabilitation Medicine
University of Cincinnati, Cincinnati, OH

Dr. Brian Moseley is an Assistant Professor in the Department of Neurology and Rehabilitation Medicine at the University of Cincinnati in Cincinnati, Ohio. Before moving to Ohio, Dr. Moseley was a Clinical Instructor at the University of California at Los Angeles (UCLA) and an Assistant Professor of Neurology at the Mayo Clinic in Rochester, Minnesota.

Dr. Moseley earned a medical degree from Loma Linda University School of Medicine in Loma Linda, California. He completed an internal medicine internship and an adult neurology residency at the Mayo School of Graduate Medical Education in Rochester, Minnesota. Dr. Moseley continued his training at UCLA with a clinical neurophysiology fellowship and an epilepsy fellowship.

Dr. Moseley has authored or co-authored 2 book chapters, 9 editorials and reviews, and 41 peer-reviewed journal articles. He has served as a reviewer for more than 15 medical journals, including Neurology; Journal of Neurology, Neurosurgery, and Psychiatry; Epilepsy & Behavior; and Epilepsy Research. Dr. Moseley is a member of the American Academy of Neurology, the American Epilepsy Society, and the American Clinical Neurophysiology Society. His primary research interest is studying autonomic effects of seizures and how they may relate to sudden unexpected death in epilepsy (SUDEP). He was the first to publish on cerebral oximetric changes during seizures using noninvasive transcutaneous near-infrared spectroscopy and how such changes relate to SUDEP risk factors. He was also the first author on a publication exploring the effects of brivaracetam on secondarily generalized tonic-clonic seizures. Dr. Moseley serves on an advisory board and speakers bureau for UCB.

Dr. Pavel Klein

Director, Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD

Dr. Klein obtained BA and MA in neuroscience degrees at Oxford University and his medical training at Cambridge University. He did his neurology residency and epilepsy fellowship at the University of Virginia, as well as subsequent fellowships in neuroendocrinology and sleep at the Beth Israel Deaconess Medical Center in Boston, MA. He was Instructor in Neurology at Harvard Medical School (1996-1999). He then became Director of the Epilepsy Program, Clinical Neurophysiology Laboratory, and of the Neuroendocrine Unit at Georgetown University Hospital (1999-2003). In 2003, he founded a private epilepsy center, the Mid-Atlantic Epilepsy and Sleep Center, where he remains Director. Dr. Klein is currently Adjunct Associate Professor of Neurology at George Washington University. Dr. Klein's clinical research subjects include novel treatments of epilepsy, dietary treatments of epilepsy in adults, prevention of epilepsy after traumatic brain injury, the effect of sex and stress hormones on epilepsy, and women with epilepsy. He has received grants from the National Institutes of Health and the American Epilepsy Society, as well as investigator-initiated study grants from several pharmaceutical companies. Dr. Klein has published more than 35 peer-reviewed articles and contributed chapters to several books on epilepsy. He acts as a reviewer for a number of neurology, epilepsy, and endocrinology journals. He has been a member of the American Epilepsy Society (AES) Scientific Program Committee, Treatment Committee, and the Health Reform Task Force, and is currently the Vice Chair of the Corporate Advisory Council and the Co-Chair of the AES Private Practice Special Interest Group. He is the co-founder and co-chair of the North American Consortium of Private Epilepsy Practices.

John G. Whitesides, PhD

Senior Clinical Program Director
UCB, Inc. Smyrna, GA

Dr. Whitesides is a Senior Clinical Program Director at UCB Biosciences in Research Triangle Park, North Carolina.

After earning his PhD in neurobiology at the Duke University in Durham, North Carolina, Dr. Whitesides began a career in clinical research, working as a clinical scientist at Cato Research and Triangle Pharmaceuticals in Durham before moving to Schwarz Biosciences and UCB Biosciences. He has been the clinical program director for development projects focusing on pharmacologic treatments for epilepsy, Parkinson disease, and restless legs syndrome. He has authored or coauthored multiple articles published in peer-reviewed scientific journals such as Neurology, Epilepsia, Epilepsy Research, Journal of Neuroscience, and Movement Disorders. He has also conducted invited lectures and presentations in his fields of research. He is a member of the American Epilepsy Society.

Dr. Patrick Kwan

Professor of Neurology, The University of Melbourne
Head of Epilepsy, The Royal Melbourne Hospital
Melbourne, Australia

Patrick Kwan is Professor of Neurology at The University of Melbourne, and Head of Epilepsy at The Royal Melbourne Hospital, Melbourne, Australia. His research interests include outcomes, pharmacology, genomics, pharmacogenetics, and the implementation of precision medicine in clinical practice. He serves as an editorial board member of Epilepsy Research, Epilepsy & Behavior, Epileptic Disorders, Seizure–European Journal of Epilepsy, and CNS Drugs. He is currently Chair of the International League Against Epilepsy (ILAE) Commission of Medical Therapies.

Martyn Wood, PhD

UCB Pharma, Braine-l'Alleud, Belgium

Dr. Martyn Wood is Director of Outsourcing and Collaborations in Discovery Research, Neurosciences with UCB BioPharma SPRL in Braine-l'Alleud, Belgium. Dr. Wood has extensive experience in neuroscience drug discovery gained at Wyeth, GlaxoSmithKline, and now UCB. Previously, Dr. Wood has also directed a master's of science program in pharmaceutical medicine at the University of Surrey, UK. He is an in vitro pharmacologist pursuing a first degree from King's College in London, UK, and a PhD from the School of Pharmacy, London. He has led research teams and project teams in preclinical drug discovery and has participated in project teams for clinical drug evaluation. He has published more than 75 articles and reviews.

Joël Mercier, PhD

Associate Director, Medicinal Chemistry, UCB Biopharma, Brussels, Belgium

Joel Mercier is Associate Director of the Medicinal Chemistry Department at UCB Biopharma in Belgium. Since 2013, he has been the Head of the Neurosciences Positron Emission Tomography (PET) Tracer Discovery Group, working in collaboration with leading PET centers worldwide to develop novel PET tracers.

Konrad J. Werhahn, MD, PhD

UCB Pharma, Monheim, Germany

Konrad J. Werhahn joined UCB Pharma in 2012 and is Senior Medical Director, Head of Clinical Strategy, Seizure Freedom Mission, PVU Neurology. Previously, Dr. Werhahn was Professor in Epileptology and Head of the Epilepsy Section at the University of Mainz, Germany. He received his neurology training at the National Hospital for Neurology, London, UK; the University of Düsseldorf, Germany; and the University of Munich, Germany. He completed postdoctoral work at the Human Cortical Physiology Section of the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health, Bethesda, MD, from 1999-2002. Original journal publications include articles in Journal of Physiology–London, Nature Neuroscience, Annals of Neurology, Brain, and Magnetic Resonance in Medicine.

Dr. Teresa Gasalla

Briviact Program Physician
Assets Development Team, Seizure Freedom Mission
Neurology Patient Value Unit
UCB Biosciences GmbH
Monheim am Rhein, Germany

Teresa Gasalla, MD, is currently the Global Program Physician for BRIVIACT in UCB´s Neurology Patient Value Unit, based in Monheim, Germany. She has supported several clinical development programs in epilepsy within UCB, including the Vimpat European monotherapy program. She is a certified neurologist and earned her medical degree from Universidad Complutense de Madrid, completing a residency at University Hospital Principe de Asturias in Alcalá de Henares, Spain. She has extensive experience in different pharmaceutical companies in both Clinical Development and Medical Affairs positions, covering a variety of therapeutic areas including epilepsy, multiple sclerosis, Parkinson disease, depression, and attention deficit hyperactivity disorder. She also worked as an attending and research physician in the Neurology Department and Multiple Sclerosis Unit in University Hospital Ramón y Cajal in Madrid.

Tony Daniels

Clinical Program Director
UCB Biosciences, Inc.
Research Triangle Park, NC

Tony is a Clinical Program Director at UCB Biosciences in Research Triangle Park, North Carolina currently working in pediatric epilepsy.

Tony earned his BS in Biology at the University of North Carolina at Chapel Hill. After graduating, he started a career in research, working in the Oncology and Dermatology departments at the North Carolina Memorial Hospital in Chapel Hill. He has over 21 years of clinical research experience and has been a clinical program director for research projects concerning pharmacologic treatments for epilepsy and restless legs syndrome. He has coauthored articles published in peer-reviewed scientific journals such as Neurology and Epilepsia. He is a member of the American Epilepsy Society.

Dr. Marc De Backer

Head of Knowledge Mobilisation
UCB Pharma, Brussels, Belgium

Dr. Marc De Backer is currently Medical Director, Head of Knowledge Mobilisation, at UCB Pharma, Brussels, Belgium. He qualified as a Doctor in Medicine from the University of Leuven, Belgium. He held medical positions in several therapeutic areas in the pharmaceutical industry before joining the global epilepsy team at UCB Pharma in 2009, where he has been mainly involved with VIMPAT (lacosamide). While active in the pharmaceutical industry, he obtained a master's degree in business administration from the University of Leuven, Belgium, and became a fellow of the Belgian College of Pharmaceutical Medicine. His interests include the development of new medicines and bringing added value to patients and health care.

Amanda Golembesky, PhD, MS

Director of Pregnancy and Pediatric Epidemiology
UCB Pharma, Raleigh, NC

Amanda Golembesky, PhD, MS, is the Head of Pregnancy, Lactation and Pediatric Epidemiology at UCB. Amanda has over 10 years of experience in real world data and joined UCB in January 2012. She provides subject matter expertise in pregnancy and pediatrics across all UCB products, ensuring that patients and their health care providers have the best data possible to make informed treatment decisions.

Soléne Thieffry, MS

Senior Health Outcomes Manager
UCB Biopharma, Brussels, Belgium

Ms Thieffry is a Senior Health Outcomes Manager in UCB Biopharma in Belgium. Since she has joined her current role 3 years ago, she has been focusing on diverse epilepsy research projects mainly to understand better the burden of the disease and ecosystem of care in children and adults epilepsy in real-world setting.

Soléne holds a bachelor's degree in biology and a master's degree in marketing management from the University of Rennes 1 in France. She has also followed an intense course of epidemiology at the London School of Hygiene and Tropical Medicine and health economics at the University of York in the UK.

Linda Kalilani, PhD

Director and Head of Epidemiology & Real World Data Science-Neurology
UCB Pharma, Raleigh, NC

Dr. Linda Kalilani obtained a PhD degree in epidemiology from the University of North Carolina in Chapel Hill. She has over 10 years' experience working in the pharmaceutical industry as an epidemiologist. Prior to joining UCB, she taught postgraduate students in public health research methodology courses and conducted clinical research at the University of Malawi. She has also consulted as an epidemiologist for the WorldWide Epidemiology Team in the infectious disease group. Dr. Kalilani joined UCB 5 years ago as a safety physician and then transitioned to her current role as Director of Epidemiology, leading the generation of evidence and using real world data to support the patient value strategy for neurology.